The regeneration of damaged or diseased human tissues using specific lineage-directed precursors could soon be possible. Pluripotent stem cell lines from human embryos have recently been established in vitro. Applying specific differentiation techniques developed for murine embryonic stem (ES) cells result in lineage-restricted cells that can integrate into damaged tissues and restore function. In addition to these embryo-derived stem cells, several reports have recently described the generation of cells of one tissue type from cells normally restricted to another lineage. However, the mechanisms directing this transdifferentiation, and the means by which these cells may be expanded are not clear. Furthermore, the control of such events in culture has yet to be developed. For this reason stem cells derived from embryos are likely to prove to be the most efficient route for tissue replacement therapy. This review outlines the embryological origins of the pluripotent stem cell lines derived from murine embryos and compares some of their characteristics with those of their human counterparts.
Stem cells of the early mouse embryo
The embryos of many vertebrates develop in a pattern that is dictated by cytoplasmic determinants in the egg. The mammalian embryo, however, stands alone in its impressive capacity to develop normally after cell ablation or relocation of cells during cleavage. For example, at the 2-cell stage the mouse embryo can be separated into blastomeres that can each develop into a perfectly normal animal. In rabbits and sheep, blastomeres isolated at the 8-cell stage can give rise to normal individuals. Removal of blastomeres from the 16-cell stage mammalian embryo does not result in loss of any specific structure, as occurs for example after cell ablation in frog embryos. This facility for regulation has been exploited in agricultural applications with cattle and sheep to generate multiple individuals with a desirable genotype from a single embryo, simply by separation of the blastomeres during preimplantation stages. It has also been invaluable in allowing biopsy in humans for pre-gestational screening of inherited diseases in in vitro fertilisation programmes.
This flexibility, or totipotency of mammalian development is reduced as the morula becomes a blastocyst when the first tissue, the trophectoderm, differentiates on the outside of the embryo. The trophectoderm will give rise solely to structures involved in invasion of the uterus and establishment of the placenta. The remaining inside population of cells -the inner cell mass, ICM, or pluriblast -is initially totipotent, and has the capacity to regenerate the trophectoderm if the outside differentiated layer is removed. Gradually, this regenerative property is lost, but the cells of the ICM remain equivalent to one another and have the capacity to form all tissues of the foetus as well as additional extraembryonic structures. The ICM cells are now defined as pluripotent.
Just before implantation a second differentiative event occurs in the ICM, resulting in formation of the primitive endoderm or hypoblast on the surface lining the blastocyst cavity. This tissue is involved in formation of the parietal and visceral yolk sacs that will surround the foetus in utero. The remainder of the ICM is now known as the primitive ectoderm or epiblast. In the mouse the epiblast does not retain the ability to produce further hypoblast cells, but this is not a universal property of mammalian embryos, and is not shared by the rat for example, whose development is otherwise very similar.
At around the time of implantation the epiblast is merely a ball of cells, but within a few hours the cells begin to organise into a cupshaped epithelium. This event is thought to be controlled by signals from the visceral endoderm, a derivative of the primitive endoderm that surrounds the epiblast. Following implantation the epiblast enters a period of rapid cell division that persists during gastrulation. This is a time of progressive differentiation as cells of the epiblast become allocated to specific fates, depending upon whether they have passed through the primitive streak and the subsequent position they come to occupy. Interestingly, during the early stages of gastrulation ablation of up to 80% of the developing embryo does not prevent relatively normal subsequent development. By the end of gastrulation all of the epiblast cells have differentiated; only the primordial germ cells, located in the posterior region of the embryo retain the potential for development into all tissues under appropriate conditions.
Harnessing pluripotency in culture
To understand the biology of mammalian pluripotent cells and to exploit their potential uses it is desirable to be able to grow them in culture and manipulate them genetically. In the 1970s embryonal carcinoma (EC) cells were derived from teratocarcinomas generated by transferring ICM cells or epiblasts to a permissive site, such as the testis or kidney of a host animal. Teratocarcinomas consist of many differentiated cells and a population of stem cells that can induce a second tumour if transferred to another host; and can also proliferate in vitro. EC cells were the first pluripotent mammalian stem cells that could be propagated in culture. Lines have been successfully obtained using murine embryos undergoing gastrulation. When integrated into a host morula or blastocyst, derivatives from EC cells can occasionally be found in many tissues of the resulting adult mouse. However, they rarely, if ever, contribute to the germline. The establishment of murine embryonic stem (ES) cell lines was a major breakthrough in the early 80s. ES cells were derived directly in culture from ICMs, either isolated from the trophectoderm or as intact blastocysts. They have become invaluable becasue of their ability to colonise all tissues including the germline when aggregated with a host preimplantation embryo. Consequently, it is possible, using transgenic and gene targeting technology, to create mice bearing specific mutations that may be used for studies in gene function or as models for disease. In spite of persistent effort, however, in contrast to EC cells, ES cells have not yet been derived from postimplantation embryos. It is possible that epithelialisation of the epiblast may somehow inhibit the pluripotent population from overcoming its programmed differentiation when subjected to the culture conditions established for derivation of ES cells from blastocysts.
An important ingredient for ES cell derivation and propagation is leukaemia inhibitory factor (LIF). LIF is produced by the fibroblasts upon which ES cells are frequently cultured, but it may also be added to the culture medium in purified form. LIF and related cytokines operate via a receptor incorporating the cell surface glycoprotein gp130 that recruits the signal transducer and activator of transcription STAT3. Enforced activation of STAT3 in ES cells allows stem cell self-renewal even in the absence of cytokines, showing that LIF family members maintain pluripotency primarily through this signal transduction pathway.
In addition to STAT3 activation, expression of the transcription factor Oct-4 is absolutely required for ES cell self-renewal. Oct-4 expression is restricted to pluripotent stem cells in vivo and in vitro; pluripotent cells not expressing Oct-4 are never seen. Differentiation of ES cells is associated with down regulation of Oct-4. Targeted deletion of Oct-4 results in embryos composed entirely of trophectoderm that can implant in the uterus, but fail to develop any further. In normal embryos completion of gastrulation is coincident with restriction of Oct-4 expression to the primordial germ cells. Cells resembling ES cells have been derived from the primordial germ cells of mice. These embryonic germ (EG) cells can contribute to all tissues, including the germline of chimaeras.
Pluripotent stem cell lines from human embryos
Cells resembling mouse ES cells have now been derived from surplus human embryos donated by informed, consenting couples following in vitro fertilisation treatment. It is obviously not possible to test the developmental potential of human ES cells by their contribution to chimaeras, but derivatives of all three germ layersectoderm, mesoderm and endoderm -have been generated in teratomas formed by injecting these cells into severe combined immunodeficient (SCID) mice. More specifically, Pluripotent cell lines have also been established from primordial germ cells dissected from aborted human embryos. Interestingly, these cells resemble mouse ES cells more closely than do the human blastocyst-derived cells, at least in their responsiveness to LIF and the ease with which they can be passaged. So far nothing is known about the methylation status of the imprinted genes in human EG cells. This may be a matter for concern, since relaxation of imprinting of specific genes has been associated with several human malignancies. Human EG cells have not yet been tested for their ability to differentiate along specific lineages by injection into SCID mice, but by growing them at high density in culture differentiation can be observed and markers for derivatives of all three germ layers have been identified.
The ability to derive human ES cells is a very important step towards cell replacement therapy. Demonstration of specific lineagedirected differentiation will certainly be achieved soon. By adapting the technology developed for murine ES cells, such as gene targeting, to remove incompatible genes of the histocompatibility complex, it may be possible to overcome the anticipated problems of immune rejection when clinical trials begin. ES cell lines have been derived from murine blastocysts generated by nuclear transfer into enucleated oocytes. Applying this technique using genetically matched nuclei may provide an alternative way to overcome immune rejection. However, the implications of developing such a technique using human embryos will invoke fear of the possibility of generating whole beings It may be a long time before the obvious advantages of using nuclear transfer for cell replacement therapy are allowed to emerge in clinical practice.
